| |
| |
|
| Insider
Information: |
Seidenberg Beth C |
| Relationship: |
|
| City: |
|
| State: |
|
| |
|
| Insider
Summary: |
|
|
|
|
Companies Owned : |
11 |
|
| Direct
Shares |
320,491 |
|
|
Indirect Shares
|
23,818,703 |
|
|
| Direct
Value |
$5,589,257 |
|
|
|
Indirect Value
|
$60,071,849 |
|
|
| Total
Shares |
24,139,194 |
|
|
| Total
Value |
$65,661,106 |
|
|
|
|
|
|
|
|
Historical
Performance :
Based on 6 Month Return Percentages |
Buys
|
Sells
|
|
Total
Filings :
|
3
|
0
|
|
Stock
price went up :
|
0
|
0
|
| Stock
price went down : |
3
|
0
|
| |
|
|
|
Gain/Loss Ratio : |
-3.0
|
0.0
|
| Percentage
Gain/Loss : |
 -69.3%
|
0.0%
|
| |
|
|
|
|
|
Holdings
:
| Menu |
Company Name |
Ticker |
Relation |
Direct Date |
Direct Shares |
Indirect Date |
Indirect Shares |
Total Value Sold  |
 |
Amgen Inc |
AMGN |
Sr VP, Dev & Chief Med... |
2004-12-31 |
15,343 |
2004-01-14 |
0 |
Premium* |
|
|
Biocryst Pharmaceuticals Inc |
BCRX |
Director |
2006-05-03 |
0 |
2006-05-03 |
3,000 |
Premium* |
|
|
Tesaro, Inc. |
TSRO |
Director |
2019-01-22 |
0 |
2019-01-22 |
0 |
Premium* |
|
|
Epizyme, Inc. |
EPZM |
Director |
2019-06-30 |
8,481 |
2019-06-30 |
4,115,555 |
Premium* |
|
|
Atara Biotherapeutics, Inc. |
ATRA |
|
2023-05-31 |
115,689 |
2023-05-31 |
1,877,044 |
Premium* |
|
|
Armo Biosciences Inc |
ARMO |
Director |
2018-01-30 |
0 |
2018-06-22 |
0 |
Premium* |
|
|
Progyny, Inc. |
PGNY |
Director |
2023-06-23 |
36,210 |
2023-06-23 |
5,302,521 |
Premium* |
|
|
Vera Therapeutics, Inc. |
VERA |
Director |
2021-05-18 |
0 |
2023-03-28 |
1,946,995 |
Premium* |
|
|
Acelyrin, Inc. |
SLRN |
Director, 10% Owner |
2023-05-09 |
60,000 |
2023-05-09 |
9,790,729 |
Premium* |
|
|
Sagimet Biosciences Inc. |
SGMT |
Director |
2023-07-18 |
84,768 |
2023-07-18 |
46,875 |
Premium* |
|
|
Kyverna Therapeutics |
KYTX |
|
2024-02-12 |
0 |
2024-02-12 |
735,984 |
Premium* |
|
|
|
|
|
|
|
|
|
|
|
Records found :
130 |
Free Registration Required For Full Results. Limit: 25
|
 |
Download |
Page 5 of 6
|
| Ticker |
Company Name |
Relation |
Off-Dir-10% |
Trans. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
| VERA |
Vera Therapeutics, Inc. |
Director |
– • – |
2023-02-09 |
4 |
B |
$7.25 |
$2,900 |
I/I |
400 |
1,654,630 |
2.1 |
- |
|
| VERA |
Vera Therapeutics, Inc. |
Director |
– • – |
2023-02-13 |
4 |
B |
$7.20 |
$72,490 |
I/I |
10,072 |
1,664,702 |
2.1 |
- |
|
| VERA |
Vera Therapeutics, Inc. |
Director |
– • – |
2023-02-23 |
4 |
B |
$7.24 |
$1,447 |
I/I |
200 |
1,664,902 |
2.02 |
- |
|
| VERA |
Vera Therapeutics, Inc. |
Director |
– • – |
2023-03-01 |
4 |
B |
$7.25 |
$725 |
I/I |
100 |
1,665,002 |
2.02 |
- |
|
| VERA |
Vera Therapeutics, Inc. |
Director |
– • – |
2023-03-02 |
4 |
B |
$7.24 |
$169,322 |
I/I |
23,378 |
1,688,380 |
2.1 |
- |
|
| VERA |
Vera Therapeutics, Inc. |
Director |
– • – |
2023-03-03 |
4 |
B |
$7.25 |
$7,245 |
I/I |
1,000 |
1,689,380 |
2.1 |
- |
|
| VERA |
Vera Therapeutics, Inc. |
Director |
– • – |
2023-03-10 |
4 |
B |
$7.16 |
$343,485 |
I/I |
48,003 |
1,737,383 |
2.1 |
- |
|
| VERA |
Vera Therapeutics, Inc. |
Director |
– • – |
2023-03-15 |
4 |
B |
$7.12 |
$234,010 |
I/I |
32,844 |
1,770,227 |
2.1 |
- |
|
| VERA |
Vera Therapeutics, Inc. |
Director |
– • – |
2023-03-16 |
4 |
B |
$7.09 |
$426,268 |
I/I |
60,097 |
1,830,324 |
2.1 |
- |
|
| VERA |
Vera Therapeutics, Inc. |
Director |
– • – |
2023-03-17 |
4 |
B |
$7.12 |
$526,882 |
I/I |
74,045 |
1,904,369 |
2.1 |
- |
|
| VERA |
Vera Therapeutics, Inc. |
Director |
– • – |
2023-03-20 |
4 |
B |
$7.21 |
$110,033 |
I/I |
15,252 |
1,919,621 |
2.1 |
- |
|
| VERA |
Vera Therapeutics, Inc. |
Director |
– • – |
2023-03-24 |
4 |
B |
$7.24 |
$13,272 |
I/I |
1,833 |
1,921,454 |
2.1 |
- |
|
| VERA |
Vera Therapeutics, Inc. |
Director |
– • – |
2023-03-27 |
4 |
B |
$7.24 |
$11,830 |
I/I |
1,633 |
1,923,087 |
2.1 |
- |
|
| VERA |
Vera Therapeutics, Inc. |
Director |
– • – |
2023-03-28 |
4 |
B |
$7.24 |
$173,192 |
I/I |
23,908 |
1,946,995 |
2.1 |
- |
|
| SLRN |
Acelyrin, Inc. |
Director |
– • • |
2023-05-09 |
4 |
B |
$18.00 |
$1,080,000 |
D/D |
60,000 |
60,000 |
3.92 |
% |
|
| SLRN |
Acelyrin, Inc. |
Director |
– • • |
2023-05-09 |
4 |
B |
$18.00 |
$22,500,000 |
I/I |
1,250,000 |
9,790,729 |
2.25 |
% |
|
| SLRN |
Acelyrin, Inc. |
Director |
– • • |
2023-05-09 |
4 |
A |
$0.00 |
$0 |
I/I |
8,540,729 |
8,540,729 |
0 |
- |
|
| PGNY |
Progyny, Inc. |
Director |
– • – |
2023-05-24 |
4 |
A |
$0.00 |
$0 |
D/D |
5,116 |
19,270 |
0 |
- |
|
| ATRA |
Atara Biotherapeutics, In... |
|
• • – |
2023-05-31 |
4 |
A |
$0.00 |
$0 |
D/D |
57,000 |
115,689 |
0 |
- |
|
| PGNY |
Progyny, Inc. |
Director |
– • – |
2023-06-09 |
4 |
A |
$0.00 |
$0 |
I/I |
264,608 |
264,608 |
0 |
- |
|
| PGNY |
Progyny, Inc. |
Director |
– • – |
2023-06-09 |
4 |
D |
$0.00 |
$0 |
I/I |
(1,646,346) |
17,162 |
0 |
- |
|
| PGNY |
Progyny, Inc. |
Director |
– • – |
2023-06-09 |
4 |
A |
$0.00 |
$0 |
D/D |
6,656 |
25,926 |
0 |
- |
|
| PGNY |
Progyny, Inc. |
Director |
– • – |
2023-06-23 |
4 |
A |
$0.00 |
$0 |
D/D |
10,284 |
36,210 |
0 |
- |
|
| PGNY |
Progyny, Inc. |
Director |
– • – |
2023-06-23 |
4 |
D |
$0.00 |
$0 |
I/I |
(17,162) |
0 |
0 |
- |
|
| SGMT |
Sagimet Biosciences Inc. |
Director |
– • – |
2023-07-18 |
4 |
D |
$0.00 |
$0 |
I/I |
(38,763) |
0 |
0 |
- |
|
130 Records found
|
|
Page 5 of 6 |
| |
Free Registration Required For Full Results. Limit: 25
|
|
| |
Transaction Code Key: |
Ownership Code Key |
| |
B |
- Buy |
AB |
- Automatic Buy |
D |
- Direct Ownership |
| |
S |
- Sell |
AS |
- Automatic Sell |
I |
- Indirect Ownership |
|
OE |
- Options Exercised |
A |
- Aquired |
| |
IO |
- Initital Ownership |
D |
- Disposed |
| |
|
|
|
|
|
